Outcomes of combined single-use dual blade goniotomy and cataract surgery

Sabine Baumgarten · Niklas Plange · Hla Myint Htoon · Tibor Lohmann · Andreas Videa · Antonis Koutsonas · Hannah Schellhase · David Kuerten · Peter Walter · Matthias Fuest

Received: 10 July 2021 / Accepted: 12 March 2022 / Published online: 31 March 2022
© The Author(s) 2022

Abstract

Purpose Single-use dual blade goniotomy (SBG) is a novel ab interno procedure that removes three to five clock hours of trabecular meshwork (TM). We analysed the reduction of intraocular pressure (IOP) and topical glaucoma medication (Meds) in eyes following combined cataract surgery and SBG (Cat-SBG).

Methods IOP and Meds were evaluated retrospectively in 55 eyes of 38 patients. 44 eyes had high tension glaucoma (HTG) and eleven eyes had normal tension glaucoma (NTG). Complete success (no Meds) and qualified success (with Meds) for IOP levels ≤ 21, ≤ 18, ≤ 16 mmHg or ≥ 20% IOP reduction at the two- and six-month follow-up were evaluated.

Results IOP and Meds were significantly reduced from before to two months after Cat-SBG in HTG- and NTG-patients (HTG: IOP 19.4 ± 3.3 to 15.1 ± 3.3 mmHg; p < 0.001; Meds 2.1 ± 1.3 to 0.8 ± 1.3; p < 0.001; NTG: IOP 14.0 ± 2.3 to 11.5 ± 2.3 mmHg; p = 0.004; Meds 1.6 ± 0.7 to 0.3 ± 0.7; p < 0.001). IOP and Meds did not change significantly from two to six months after Cat-SBG.

In HTG, complete and qualified success rates were 43% (19/44) and 93% (41/44) for IOP ≤ 18 mmHg, 36% (16/44) and 64% (28/44) for IOP ≤ 16 mmHg and 30% (13/44) for IOP reduction ≥ 20% six months after surgery. In NTG, complete and qualified success was 81% (9/11) and 100% (11/11) for IOP ≤ 18 and ≤ 16 mmHg, and 27% (3/11) for IOP reduction ≥ 20%.

IOP and Meds reduction were comparable between HTG and NTG eyes.

Only minor postoperative complications occurred.

Conclusion Cat-SBG is an efficient method to significantly lower IOP in patients with HTG and NTG.

Keywords Glaucoma · Intraocular pressure · Single-use dual blade goniotomy · Kahook Dual Blade goniotomy
Introduction

Glaucoma is a leading cause of blindness [1], and the reduction of intraocular pressure (IOP) is considered to decelerate its progression [2, 3]. Obstruction of aqueous outflow at the level of juxtacanalicular trabecular meshwork (TM) and distal outflow structures is a major component of IOP dysregulation [4, 5]. Performing trabeculotomy or goniotomy in adults with glaucoma showed variable success rates [6, 7]; an incomplete removal of TM and membrane formation across the remaining TM leaflets leading to subsequent IOP elevation has been reported [6–8].

Single-use dual blade goniotomy (SBG) is a minimally invasive glaucoma surgery (MIGS) that removes an approximately 230 µm wide strip of TM with two blades via an ab interno approach [9, 10]. Three to five clock hours of TM circumference are removed so that the resistance of the aqueous outflow pathway is decreased [11, 12]. Compared to traditional ab externo trabeculotomies, a complete excision of the TM tissue is achieved instead of only an incision [11, 13]. By minimizing residual TM leaflets, the development of fibrosis is reduced and thus, SBG potentially surpasses outcomes of traditional ab externo trabeculotomy in adults [12]. Recent studies showed convincing success rates for the SBG procedure at reducing IOP and glaucoma medication (Meds) as a standalone procedure or combined with cataract surgery [12, 14–16].

While Cat-SBG has shown good results in patients with HTG [15, 17, 18], there are currently no data on the effect in NTG patients.

In this study, we examined Cat-SBG outcomes performed at two specialized centres and analysed success rates in patients with mild to advanced high-tension glaucoma (HTG) as well as in patients with normal tension glaucoma (NTG).

Patients and methods

Included in this retrospective study were 55 eyes of 38 patients. 44 eyes of 31 patients had HTG (primary open-angle glaucoma (POAG, n = 33), pseudoexfoliation glaucoma (PEX, n = 11)). 16 HTG patients were female, 15 male and 23 right eyes and 21 left eyes were included. The mean age of HTG patients was 74 ± 9 years (49 to 87 years).

Eleven eyes of seven patients had NTG. Three NTG patients were female and four were male. The mean age of NTG patients was 68 ± 12 years (49 to 81 years).

Patients had mild to advanced glaucoma according to Hodapp et al. [19] (mild = 40, moderate = 10, advanced = 5). Visual field defects were documented by static computerized perimetry, using the Humphrey 24–2 Swedish Interactive Thresholding Algorithm (SITA) program (Carl Zeiss Meditec, Jena, Germany). MD was −8.1 ± 6.8 dB (−22.6 to −0.18 dB) in HTG eyes and −5.9 ± 11.4 dB (−23.0 to −0.25 dB) in NTG eyes.

All eyes underwent combined Cat-SBG. All procedures were performed following a standardized protocol between August 2017 and May 2020. SBG was only performed after uneventful cataract surgery. Indication for Cat-SBG was the aim to reduce the dependence on IOP lowering eye drops and to improve the IOP level. The procedure was recommended in all glaucoma patients taking IOP lowering eye drops or ocular hypertension planned for cataract surgery.

Meds, IOP values and complications were evaluated two and six months after Cat-SBG. Complete success, referring to patients that reached the target IOP without Meds, and qualified success, reaching target IOP irrespective of Meds, were evaluated at the two- and six-month follow-up for IOP ≤ 21, ≤ 18 and ≤ 16 mmHg as well as ≥ 20% IOP reduction.

The Institutional Ethical Review Board of the RWTH Aachen University approved the study (EK 410/20). The described research adhered to the tenets of the Declaration of Helsinki.

Surgical technique

Phacoemulsification (phaco) with in the bag implantation of a foldable acrylic lens (CT Asphina 409MP, Carl Zeiss Meditec, Jena, Germany) was performed under regional (topical and intraocular) anaesthesia. Then, to constrict the pupil, acetylcholine chloride 1% (Miochol-E, Dr. Gerhard Mann, Berlin, Germany) was instilled into the anterior chamber. To deepen the chamber angle, a cohesive viscoelastic (sodium hyaluronate 1%, Healon Pro, Johnson & Johnson, New Brunswick, USA) was injected into the nasal anterior chamber (AC) angle. The angulation of the
microscope (OPMI VISU 210, S8, Carl Zeiss Meditec, Jena, Germany) was adjusted, and the patient’s head tilted to allow visualization of the nasal AC angle through a single-use gonioprism lens (MV LV 48, Phakos, Montreuil, France). The blade (Kahook Dual Blade, New World Medical, Rancho, CA, USA) was introduced through the temporal paracentesis initially used for cataract surgery. The TM excision with the single-use dual blade (SDB) was started at the midnasal 3/9 o’clock position and then advanced inferiorly (Fig. 1). The sharp tip of the SDB was inserted through the TM and into Schlemm’s canal (SC). The heel of the SDB was seated against the wall of SC, and the blade was advanced within the canal. Then, the SDB was slightly withdrawn, turned and another cut performed from the 3/9 o’clock position superiorly. Total TM excision was three to five clock hours. In this way, two strips of TM were generated. In case of a large, mobile strip, a 23G intraocular forceps (Geuder AG, Heidelberg, Germany) was used to remove it through the temporal paracentesis to avoid incarceration (n = 2). After flushing out the viscoelastic from the anterior chamber, acetylcholine chloride 1% was injected again to further constrict the pupil.

After surgery, patients were treated with topical antibiotics (ofloxacin 0.3%, Floxal EDO, Dr. Gerhard Mann, Berlin, Germany) and prednisolone acetate 1% eye drops (Inflanefran forte, Allergan, Frankfurt am Main, Germany) every two hours for one week, followed by three times daily until for two weeks postoperatively to avoid infection and inflammation.

### Statistical analysis

All values were expressed as the mean ± standard deviation (range: minimum to maximum).

Statistical analysis was performed using IBM SPSS Statistics for Macintosh, Version 26.0, Armonk, NY: CBM Corp. The changes in IOP and Meds over...
time were investigated using a linear mixed model to account for fellow-eye correlations (utilizing an autoregressive first-order correlation co-variance structure based on smaller the better, Hurvich’s & Tsai’s (AICC) information criterion), and Bonferroni’s correction was used to address multiplicity. Comparisons between categorical variables were conducted using the Fisher’s exact test. According to Kolmogorov–Smirnov tests, all parameters were identified as normally distributed. A $P$-value of $< 0.05$ was considered statistically significant.

### Results

A summary for patients’ characteristic is presented in Table 1.

In all patients, Cat-SBG could be performed as planned after uncomplicated cataract surgery. No patient was considered a failure due to severe complications or needed additional glaucoma surgery during follow-up.

**HTG eyes**

Mean IOP before Cat-SBG was $19.4 \pm 3.3$ mmHg (16 to 29 mmHg) under $2.1 \pm 1.3$ (0.0 to 4.0) Meds (Fig. 2 and Table 2).

Mean IOP decreased significantly from before to two months after Cat-SBG (IOP $15.1 \pm 3.3$ mmHg (10 to 20 mmHg); $p < 0.001$). The number of Meds was significantly reduced to $0.8 \pm 1.3$ (0 to 4.0) ($p < 0.001$) two months after Cat-SBG. IOP and Meds did not increase from two months until six months after Cat-SBG (IOP $15.2 \pm 3.3$ mmHg (10 to 20 mmHg); $p = 1.0$; Meds $0.7 \pm 1.3$ (0 to 3.0); $p = 1.0$).

Two months after Cat-SBG, complete success and qualified success were 55% (24/44) and 100% (44/44) for IOP $\leq 21$ mmHg, 50% (22/44) and 90% (40/44) for IOP $\leq 18$ mmHg, 36% (16/44) and 65% (29/44) for IOP $\leq 16$ mmHg as well as 29% (13/44) and 52% (23/44) for $\geq 20\%$ IOP reduction. Six months after Cat-SBG, complete success and qualified success were 57% (25/44) and 100% (44/44) for IOP $\leq 21$ mmHg, 43% (19/44) and 93% (41/44) for IOP $\leq 18$ mmHg, 36% (16/44) and 64% (28/44) for IOP $\leq 16$ mmHg as well as 30% (13/44) and 43% (19/44) for $\geq 20\%$ IOP reduction (Table 2 and Fig. 3).

**NTG eyes**

Mean IOP before Cat-SBG was $14.0 \pm 2.3$ mmHg (12.0 to 19.0 mmHg) under $1.6 \pm 0.7$ (1.0 to 4.0) Meds (Table 2 and Fig. 4). Mean IOP decreased significantly from before to two months after Cat-SBG (IOP $11.5 \pm 2.3$ mmHg (9.0 to 15.0 mmHg); $p = 0.004$). The number of Meds decreased significantly from before to 2 m ($p < 0.001$) with no further significant changes to the 6 m follow-up

| Parameters                      | HTG ($n = 31/38$ (82.6%)) | NTG ($n = 7/38$ (18.4%)) | $P$ value |
|--------------------------------|---------------------------|---------------------------|-----------|
| Number of eyes (n)              | 44 (80%)                  | 11 (20%)                  | 0.733     |
| Sex                            | 16 (51.6%)                | 3 (42.9%)                 |           |
| Female (n)                     | 14 (36.8%)                | 4 (57.1%)                 |           |
| Male (n)                       |                           |                           |           |
| Right eyes (n)                 | 23 (53.3%)                | 6 (54.5%)                 | 1.0       |
| Left eyes (n)                  | 21 (47.7%)                | 5 (45.5%)                 |           |
| Mean age ± SD (years)          | $74 \pm 9$ (49 to 87)     | $68 \pm 12$ (49 to 81)    | 0.020*    |
| Mean deviation ± SD (dB)       | $-8.1 \pm 6.8$ (-22.6 to -0.18) | $-5.9 \pm 11.4$ (-23 to -0.25) | 0.569     |

*Indicates significant difference ($P < 0.05$)
### Table 2

Intraocular pressure (IOP) and topical glaucoma medication (Meds) before combined cataract surgery and single-use dual blade goniotomy (Cat-SBG) and at different time points after Cat-SBG for high-tension glaucoma (HTG) eyes and normal tension glaucoma (NTG) eyes

|                      | HTG (n = 44) before Cat-SBG | HTG (n = 44), two months after Cat-SBG | HTG (n = 44), six months after Cat-SBG | NTG (n = 11), before Cat-SBG | NTG (n = 11), two months after Cat-SBG | NTG (n = 11), six months after Cat-SBG |
|----------------------|----------------------------|----------------------------------------|----------------------------------------|-----------------------------|----------------------------------------|----------------------------------------|
| IOP ± SD (mmHg)      | 19.4 ± 3.3                 | 15.1 ± 3.3*                            | 15.2 ± 3.3*                            | 14.0 ± 2.3                  | 11.5 ± 2.3*                            | 12.4 ± 2.3*                            |
| Meds ± SD            | 2.1 ± 1.3                  | 0.8 ± 1.3*                             | 0.7 ± 1.3*                             | 1.6 ± 0.7                   | 0.3 ± 0.7*                             | 0.2 ± 0.7*                             |
| Complete success rates (%) for IOP ≤ 21 mmHg (n =) | –                           | 55 (24/44)                             | 57 (25/44)                             | –                           | 73 (8/11)                              | 81 (9/11)                              |
| Complete success rates (%) for IOP ≤ 18 mmHg (n =) | –                           | 50 (22/44)                             | 43 (19/44)                             | –                           | 73 (8/11)                              | 81 (9/11)                              |
| Complete success rates (%) for IOP ≤ 16 mmHg (n =) | –                           | 36 (16/44)                             | 36 (16/44)                             | –                           | 73 (8/11)                              | 81 (9/11)                              |
| Complete success rates for ≥ 20% IOP reduction (n =) | –                           | 29 (13/44)                             | 30 (13/44)                             | –                           | 27 (3/11)                              | 27 (3/11)                              |
| Qualified success rates (%) for IOP ≤ 21 mmHg (n =) | –                           | 100(44/44)                             | 100(44/44)                             | –                           | (100 (11/11))                         | (100 (11/11))                         |
| Qualified success rates (%) for IOP ≤ 18 mmHg (n =) | –                           | 90 (40/44)                             | 93 (41/44)                             | –                           | 100 (11/11)                           | 100 (11/11)                           |
| Qualified success rates for IOP ≤ 16 mmHg (n =) | –                           | 65 (29/44)                             | 64 (28/44)                             | –                           | 100 (11/11)                           | 100 (11/11)                           |
| Qualified success rates for ≥ 20% IOP reduction (n =) | –                           | 52 (23/44)                             | 43 (19/44)                             | –                           | 64 (7/11)                              | 27 (3/11)                              |

*Indicates significant changes compared to before Cat-SBG (p < 0.05). There were no further significant changes in IOP or Meds between the consecutive follow-up visits

Complete success rates (%) (no topical glaucoma medication (Meds)) and qualified success rates (%) (irrespective of Meds) for IOP levels ≤ 21, ≤ 18, ≤ 16 mmHg as well as ≥ 20% IOP reduction at two and at six months after Cat-SBG for HTG eyes and NTG eyes

$n =$ number of eyes

---

**Fig. 3** Success rates for high tension glaucoma (HTG) and normal tension glaucoma (NTG) eyes six months after single-use dual blade goniotomy with cataract surgery (Cat-SBG). Success rates for IOP ≤ 21 mmHg in NTG eyes not included
after Cat-SBG. IOP and Meds did not increase from two until six months after Cat-SBG (IOP 12.4 ± 2.3 mmHg (10.0 to 15.0 mmHg);  
\( p = 0.706 \); Meds 0.2 ± 0.7 (0 to 1.0);  
\( p = 1.0 \)).

Two months after Cat-SBG, complete success and qualified success were 73% (8/11) and 100% (11/11) for IOP (≤ 21), ≤ 18 and ≤ 16 mmHg as well as 27% (3/11) and 64% (7/11) for ≥ 20% IOP reduction. Six months after Cat-SBG, complete success and qualified success were 81% (9/11) and 100% (11/11) for IOP ≤ 18 and ≤ 16 mmHg as well as 27% (3/11) and 27% (3/11) for ≥ 20% IOP reduction (Table 2 and Fig. 3).

**Complications**

No intraoperative complications occurred. Mild anterior chamber bleeding was considered as a sign of successful removal of the trabecular meshwork. Three eyes had a mild to moderate fibrin reaction in the first two weeks after surgery which resolved in all cases under hourly prednisolone acetate 1% eye drop therapy within the next two weeks. In one patient, the fibrinous membrane had to be opened using an yttrium–aluminium–garnet laser (Visulas YAG II, Carl Zeiss Meditec AG, Jena, Germany). Two eyes showed a mild macular edema after surgery: one eye showed the macular edema one week after surgery. Four weeks later, the edema had resolved completely using nepafenac 3 mg/ml eye drops once daily (Nevanac 3 mg/ml, Novartis, Basel, Schweiz) and acetazolamide 250 mg (Glaupax 250 mg, OmniVision GmbH, Puchheim, Germany) twice daily for two weeks. The other eye developed the macular edema four months after surgery, which resolved four weeks later using nepafenac 3 mg/ml eye drops once daily. Three eyes showed a transient IOP spike ≥ 25 mmHg in the first postoperative week. All these eyes had a normotensive IOP at the next follow-up without any further intervention. One eye showed a raised IOP due to a steroid response nine days after Cat-SBG. Prednisolone acetate 1% eye drop therapy was stopped, and loteprednol 0.5% (Lotemax 5 mg/ml, Dr. Gerhard Mann, Berlin, Germany) as well as dorzolamide 2%/timolol 0.5% (Dorzocomp Vision, OmniVision GmbH, Puchheim, Germany) and latanoprost 50 µg/ml (Monoprost, Théa Pharma GmbH Berlin, Germany) were started. At the consecutive follow-ups, IOP was ≤ 21 mmHg.

**Discussion**

In this study, we analysed 55 eyes with HTG (\( n = 44 \)) and NTG (\( n = 11 \)) undergoing Cat-SBG. In HTG eyes, we found a significant reduction in IOP (21%) and Meds (67%) from before to six months after surgery leading to complete and qualified success in 43% (19/44) and 93% (41/44) of eyes for an IOP ≤ 18 mmHg.

Separately, we analysed eleven eyes with NTG and found a lesser reduction in IOP (11%) from before to six months after Cat-SBG. Meds were
reduced by 87%. When target IOP was defined as ≤ 16 mmHg, complete success and qualified success were 81% (9/11) and 100% (11/11).

No severe intra- or postoperative complications occurred during the six months of follow-up.

In recent years, MIGS procedures have been gaining popularity as they are considered safe, effective and minimally invasive. Ab interno approaches ensure minimal disruption of normal ocular physiology and anatomy as well as a rapid visual recovery [20]. They are routinely performed in mild to moderate glaucoma to reduce Meds and to lower IOP as an early intervention without first exhausting all laser treatments and medication classes [21–24].

Previous studies on Cat-SBG with short (≤ six months) [17, 18, 25, 26] and with longer follow-ups (six to twelve months) showed promising results [12, 14–16, 24, 27]: IOP and Meds were significantly reduced from before surgery to the six- or twelve-month follow-up (see also Table 3).

In a recent application study, twelve-month results of 52 patients undergoing Cat-SBG were presented. Here, IOP was reduced from 16.8 ± 0.6 mmHg before the intervention to 12.4 ± 0.3 mmHg (p < 0.001) twelve months after surgery which corresponds to an IOP reduction of 26.2% [15]. 63.5% of patients could at least reduce eye drops by one agent [15].

Our study showed comparable results to previous Cat-SBG studies. The lesser IOP reduction in our study compared to the study by El Mallah et al. [27] (31.9%) and Berdahl et al.[25] (36.2%) could be due to the fact that eyes with a higher preoperative IOP are more likely to experience a larger effect on IOP reduction from glaucoma surgery than eyes with lower preoperative IOP [25, 28–30].

New trabeculotomy-derived surgeries [31] include the trabectome procedure [32], the microhook ab interno trabeculotomy [33], the ab interno 360° suture trabeculotomy/gonioscopy-assisted transluminal trabeculotomy [34] and the single-use dual blade goniotomy [11, 31], analysed in this study.

### Table 3: Overview of single-use dual blade goniotomy (SBG) publications. Intraocular pressure (IOP), topical glaucoma medication (Meds) before (preop) SBG and six and twelve months postoperatively (postop) with (yes) or without (no) combined cataract surgery (Cat-SBG) or with both variants of operation methods included in the analysis (both)

| Study                | n  | IOP (mmHg); Meds preop | IOP (mmHg); Meds six months postop | IOP reduction (%) preop to six months postop | Meds reduction preop to six months postop | IOP (mmHg); Meds twelve months postop | Combined cataract surgery |
|----------------------|----|------------------------|----------------------------------|---------------------------------------------|-----------------------------------------|---------------------------------------|--------------------------|
| Hirabayashi 2019 [17]| 42 | 17.1 ± 4.8; 2.4 ± 1.3  | 15.0 ± 3.0; 1.2 ± 1.4            | 12.3                                        | 1.2                                      | –                                     | Yes                      |
| Greenwood 2017 [18]  | 71 | 17.4 ± 5.2; 1.6 ± 1.3  | 12.8 ± 2.6; 0.9 ± 1.0 (n = 60)   | 26.4                                        | 0.7                                      | –                                     | Yes                      |
| Salinas 2018 [26]    | 52 | 18.4 ± 6.1; 2.6 ± 1.1  | 13.9 ± 3.5; 1.4 ± 1.1            | 24.5                                        | 1.2                                      | –                                     | No                       |
| Berdahl 2018 [25]    | 53 | 23.5 ± 1.1; 2.5 ± 0.2  | 15.0 ± 0.6; 1.5 ± 0.2            | 36.2                                        | 1                                        | –                                     | No                       |
| Dorairaj 2018 [15]   | 52 | 16.8 ± 0.6; 1.6 ± 0.2  | 12.7 ± 0.4; 0.8 ± 0.1            | 24.4                                        | 0.8                                      | 12.4 ± 0.3; 0.8 ± 0.1 Yes             |                         |
| Sieck 2018 [12]      | 197| 17.3 ± 0.4; 2.1 ± 0.1  | 14.2 ± 0.3; 1.4 ± 0.1 (n = 162)  | 17.9                                        | 0.7                                      | 13.9 ± 0.3; 1.6 ± 0.1 Both (n = 140) |                         |
| Wakil 2020 [16]      | 116| 18.0 ± 6.7; 2.5 ± 1.2  | 14.5 ± 4.6; 1.5 ± 1.3 (n = 85)   | 19.4                                        | 1                                        | 14.6 ± 4.8; 1.5 ± 1.3 Both            |                         |
| Kornmann 2019 [14]   | 111| 17.1 ± 4.7; 2.4 ± 1.3  | 14.1 ± 3.8; 1.0 ± 1.4            | 17.5                                        | 1.4                                      | 14.7 ± 3.5; 1.1 ± 1.3 (n = 72) Both   |                         |
| ElMallah 2020 [27]   | 42 | 21.6 ± 0.8; 2.5 ± 0.2  | 14.7 ± 0.7; 1.8 ± 0.2 (n = 36)   | 31.9                                        | 0.7                                      | 16.5 ± 0.8; 2.2 ± 0.2 No              |                         |
Elevated IOP due to increased resistance to aqueous humour outflow within the TM is considered an important risk factor for POAG [5, 35]. The basic principle of the trabeculotomy techniques is incising or removing TM to lower the outflow resistance, leading to improved IOP levels [31]. The goal of these new techniques is inter alia sparing of conjunctival and scleral incisions, the minimal invasiveness to the ocular surface with less induced postoperative astigmatism and the direct visualization of the anterior-chamber angle with its easier identification of SC compared with identification of TM and SC under the scleral flap during conventional ab externo trabeculotomy [31].

Trabectome is an electrosurgical ab interno procedure that was invented by George Baerveldt and first used in the USA in 2006 [32]. A bipolar 550 kHZ electrode is used to ablate the TM through gonioscopic view [32]. The trabectome system consists of four components: the disposable hand piece, the foot pedal, the cautery generator with a peristaltic irrigation-aspiration and the stand [36]. In a prospective observational study on the outcome of the trabectome (Neomedix, Tustin, CA, USA) in 261 eyes classified as POAG an overall IOP reduction of 25% was reached with a simultaneous reduction in Meds of 43% after a follow-up of 204 ± 278 days [37]. This study showed similar or rather slightly better IOP reduction rates than our study (21%); however, Meds reduction was greater in our study (67%). A pleasant aspect of SBG surgery compared to the trabectome technique is a shorter preparation time as there is no irrigation system that has to be primed and connected [9] and lower costs as the trabectome technology requires the purchase of trabectome equipment that appears to be expensive. Medium-term IOP reduction between the single-use dual blade and trabectome was not differing due to their experience, but long-term results of several years are lacking [9].

Another ab interno technique where a 360° trabeculotomy is performed was recently described by Grover et al. [38]. Hirabayashi and colleagues compared surgical outcomes of 360° circumferential trabeculotomy ab interno (360°Trab), accomplished by Trab360, Sight Sciences, Inc. Menlo Park, CA or gonioscopy-assisted transluminal trabeculotomy (GATT)) versus sectoral excisional goniotomy with the SBG technique at six months [24]. They found out that both SBG and 360°Trab similarly lowered both IOP and the need for IOP-lowering medications during the first six postoperative months [24]. They observed more eyes undergoing SBG than 360°Trab attained target IOP ≤ 18 mmHg (80.0% (56/70) vs 59.3% (16/27), p = 0.040) and ≤ 15 mmHg (61.4% (43/70) vs 25.9% (7/27), p = 0.003) six months after surgery [24]. They concluded that a full 360° trabecular bypass may not be necessary to achieve maximal efficacy from this class of micro-invasive glaucoma procedures [24].

The majority of trabeculotomy procedures employ a 120-degree trabecular meshwork incision [39]. In our study, 90- to 120-degrees of TM were excised with the majority of procedures having a hundred degrees trabeculotomy.

Another MIGS procedure is the trabecular micro-bypass stent, commonly known as iStent [20]. Aqueous humour drains directly from the anterior chamber into SC bypassing the dysfunctional TM after iStent implantation [40]. Multiple recent studies reported safety and success of the procedure [41–43], and differences in outcome between single versus multiple iStents have been reported [44–46]. A metaanalysis by Popovic et al. reported a significantly higher IOP reduction when implanting two stents compared to one (p < 0.001) and a lower postoperative IOP in eyes with two stents compared to eyes with one stent [47].

In comparison with SBG, only a small TM bypass is produced so the question arises how much of TM to be bypassed or removed and to what extent the transtrabecular flow has to be enhanced to achieve best IOP levels. Further studies have to investigate whether the IOP reducing effect is dependent on the area of “treated” TM and to what extent.

The IOP lowering effect of phaco has been described extensively; thereby, a combined approach of glaucoma surgery and phaco poses an inherent confounding factor [48–50]. Recent studies confirmed the significant IOP reduction after modern phaco cataract surgery and the IOP reduction was generally proportional to the level of preoperative IOP [51–57]. Bhallil et al. found a mean IOP reduction after phaco of 2.3 mmHg in 273 normal patients [58]; Kim et al. reported a mean decrease in IOP of 2.9 mmHg in 31 POAG patients [59].

The additional effect of phaco in Cat-SBG has still to be analysed in further studies.

A particular and important aspect of our study was the separate analysis of Cat-SBG in NTG patients:
An IOP reduction of 11% was seen from before to six months after Cat-SBG. This IOP reduction was lesser than in HTG eyes (21%), but did not reach significance. This might be due to the small sample size in our NTG group. The lesser IOP reduction in NTG eyes was expectable though as IOP before Cat-SBG was already low with 14.0 ± 2.3 mmHg in NTG eyes. Meds reduction was 87% which indicates that Cat-SBG is just as well a reasonable procedure in NTG eyes, especially when the aim is to reduce or abolish glaucoma eye drop therapy because of Meds intolerance or patient’s incompliance to use Meds. IOP can be theoretically determined by the Goldman equation, which is \( \text{IOP} = (F/C) + P \), where \( F \) represents aqueous flow rate, \( C \) represents aqueous outflow, and \( P \) is the episcleral venous pressure [60, 61]. A change or fluctuation in any of these variable is expected to alter the IOP [61]. Presuming a higher outflow resistance in HTG eyes compared to NTG eyes, we expected the SBG effect on IOP reduction being significantly higher in HTG eyes; this trend is to be seen, but our results did not reach significance, most probably due to the small sample size in our NTG group. We think this analysis is important as our study is the first study on Cat-SBG procedures that differentiates and compares success rates in HTG eyes with NTG eyes and that indicates that Cat-SBG might be successful in patients at various levels of preoperative IOP.

The efficacy of MIGS in NTG in general has yet to be established. Most MIGS procedures have not been analysed in NTG eyes. The following two studies are available: a study by Neuhammer and Neuhammer demonstrated a 21.1% IOP reduction twelve months postoperatively in a subgroup of 18 NTG patients treated with iStent inject with combined phaco (\( p = 0.01 \)) [62]. The proportion of medication-free eyes increased significantly from baseline to twelve months (\( p < 0.001 \)) [62].

The case series by Chang et al. was the first report of a variety of MIGS procedures in 45 NTG patients [30]. IOP decreased from 13.7 to 12.3 mmHg (\( p = 0.041 \)) at 2.5 years, and Meds decreased from 2.0 to 1.1 (\( p < 0.001 \)) at 1.5 years in the overall cohort [30]. Although postoperative IOP was significantly lower at all follow-up visits compared to preoperative IOP the IOP reduction rarely achieved 30% [30]. Furthermore, they analysed a subgroup of 16 patients who underwent two MIGS procedures with different mechanisms of action and found out that Meds reduction at the last follow-up was greater with 68.8% versus 35.7% in patients with single MIGS procedures which strongly trended towards significance (\( p = 0.052 \)) [30]. Further studies on success rates in NTG populations are needed to better understand the role of MIGS in these patients.

Limitations of this study include a small NTG subgroup and only six months of follow-up. Cat-SBG is a new procedure, and long-term results are still lacking. However, we believe reporting early results of a novel surgical approach are important to highlight and further propagate the Cat-SBG method. Future studies with larger Cat-SBG cohorts are planned to perform further subgroup analysis and to identify prognostic factors for this method.

We had two HTG eyes of one patient without any local antiglaucoma therapy where we performed Cat-SBG surgery. This patient had an absolute intolerance to local glaucoma medication and was referred to us for further treatment without any local Meds. Before surgery the IOP was 21 mmHg in the right and 25 mmHg in the left eye. After combined SBG, the IOP normalized to 14 and 15 mmHg at three months and to 15 and 13 mmHg at six months without Meds. We think it is acceptable to include this patient in our analysis.

Finally, the results of this study are promising and show that Cat-SBG as a minimal-invasive method significantly lowers IOP and Meds up to six-month follow-up in HTG as well as in NTG eyes. No other previous study has specifically analysed Cat-SBG effect in NTG eyes. This study shows that Cat-SBG is efficient in patients at various levels of preoperative IOP.

Funding Open Access funding enabled and organized by Projekt DEAL. No funding was received for this research.

Declarations

Conflict of interest Sabine Baumgarten, Niklas Plange, Tibo Lohmann, Andreas Videa, Antonis Koutsouonas, Hannah Schellhase, David Kuerten, Peter Walter and Matthias Fuest declare that they have no affiliations with or involvement in any organisation or entity with any financial interest (such as honorary; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.
Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee (Medical Ethical Review Board, University RWTH Aachen) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent Informed consent was obtained from all individual participants included in the study.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Quigley HA, Broman AT (2006) The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 90:262–267. https://doi.org/10.1136/bjo.2005.081224
2. Kass MA, Heuer DK, Higginbotham EJ et al (2002) The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 120:701–713. https://doi.org/10.1001/archoph.120.6.701
3. Heijl A, Leske MC, Bengtsson B et al (2002) Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 120:1268–1279. https://doi.org/10.1001/archoph.120.10.1268
4. Tamm ER (2009) The trabecular meshwork outflow pathways: structural and functional aspects. Exp Eye Res 88:648–655. https://doi.org/10.1016/j.exer.2009.02.007
5. Grant WM (1951) Clinical measurements of aqueous outflow. Am J Ophthalmol 34:1603–1605
6. Lunza MH, Livingston DG (1977) Trabeculotomy ab externo and trabeculectomy in congenital and adult-onset glaucoma. Am J Ophthalmol 83:174–179. https://doi.org/10.1016/0002-9394(77)90612-2
7. Herschler J, Davis EB (1980) Modified goniotomy for inflammatory glaucoma. Histologic evidence for the mechanism of pressure reduction. Arch Ophthalmol 98:684–687. https://doi.org/10.1001/archoph.1980.0102030678006
8. Francis BA, See RF, Rao NA et al (2006) Ab interno trabeculectomy: development of a novel device (Trabectome) and surgery for open-angle glaucoma. J Glaucoma 15:68–73. https://doi.org/10.1097/01.jig.0000196533.77836.af
9. van Oterendorp C, Bahlmann D (2019) Kahook Dual Blade: An instrument for microincisional trabecular meshwork surgery. Ophthalmologe 116:580–584. https://doi.org/10.1007/s00347-018-0844-4
10. Ammar DA, Seibold LK, Kahook MY (2020) Preclinical investigation of goniotomy using four different techniques. Clin Ophthalmol 14:3519–3525. https://doi.org/10.2147/OPTH.S281811
11. Seibold LK, Soohoo JR, Ammar DA et al (2013) Preclinical investigation of ab interno trabeculectomy using a novel dual-blade device. Am J Ophthalmol 155(524–529):e522. https://doi.org/10.1016/j.jafo.2012.09.023
12. Sieck EG, Epstein RS, Kennedy JB et al (2018) Outcomes of Kahook Dual Blade Goniotomy with and without Phacoemulsification cataract extraction. Ophthalmol Glaucoma 1.75–81. https://doi.org/10.1016/j.gla.2018.06.006
13. Barbosa NB, Grippo TM (2020) Excisional goniotomy with Kahook Dual Blade in a patient with glaucoma secondary to Transthyretin Amyloidosis. Am J Ophthalmol Case Rep 19:100750. https://doi.org/10.1016/j.ajoc.2020.100750
14. Kornmann HL, Fellman RL, Feuer WJ et al (2019) Early results of goniotomy with the Kahook Dual Blade, a novel device for the treatment of glaucoma. Clin Ophthalmol 13:2369–2376. https://doi.org/10.2147/OPTH.S24643
15. Dorairaj SK, Seibold LK, Radcliffe NM et al (2018) 12-Month outcomes of goniotomy performed using the Kahook Dual Blade Combined with cataract surgery in eyes with medically treated Glaucoma. Adv Ther 35:1460–1469. https://doi.org/10.1007/s12325-018-0755-4
16. Wakil SM, Birnbaum F, Vu DM et al (2020) Efficacy and safety of a single-use dual blade goniotomy: 18-month results. J Cataract Refract Surg 46:1408–1415. https://doi.org/10.1097/jcrs.0000000000000263
17. Hirabayashi MT, King JT, Lee D et al (2019) Outcome of phacoemulsification combined with excisional goniotomy using the Kahook Dual Blade in severe glaucoma patients at 6 months. Clin Ophthalmol 13:715–721. https://doi.org/10.2147/OPTH.S196105
18. Greenwood MD, Seibold LK, Radcliffe NM et al (2017) Goniotomy with a single-use dual blade: short-term results. J Cataract Refract Surg 43:1197–1201. https://doi.org/10.1016/j.jcrs.2017.06.046
19. Hodapp E, Parrish R, Anderson DR. Clinical Decisions In Glaucoma. In: 1993:
20. Saheb H, Ahmed II (2012) Micro-invasive glaucoma surgery: current perspectives and future directions. Curr Opin Ophthalmol 23:96–104. https://doi.org/10.1097/ICU.0b013e32834ff167
21. Richter GM, Coleman AL (2016) Minimally invasive glaucoma surgery: current status and future prospects. Clin Ophthalmol 10:189–206. https://doi.org/10.2147/OPTH.S80490
22. Agrawal P, Bradshaw SE (2018) Systematic literature review of clinical and economic outcomes of
micro-invasive Glaucoma surgery (MIGS) in primary open-angle Glaucoma. Ophthalmol Ther 7:49–73. https://doi.org/10.1007/s40123-018-0131-0

23. Bovee CE, Pasquale LR (2017) Evolving surgical interventions in the treatment of Glaucoma. Semin Ophthalmol 32:91–95. https://doi.org/10.1080/08820538.2016.1228393

24. Hirabayashi MT, Lee D, King JT et al (2019) Comparison Of Surgical Outcomes Of 360 degrees Circumferential Trabeculotomy Versus Sectoral Excisional Goniotomy With The Kahook Dual Blade At 6 Months. Clin Ophthalmol 13:2017–2024. https://doi.org/10.2147/OPTH.S208468

25. Berdahl JP, Gallardo MJ, ElMallah MK et al (2018) Six-Month Outcomes of Goniotomy Performed with the Kahook Dual Blade as a Stand-Alone Glaucoma Procedure. Adv Ther 35:2093–2102. https://doi.org/10.1007/s12325-018-0803-0

26. Salinas L, Chaudhary A, Berdahl JP et al (2018) Goniotomy Using the Kahook Dual Blade in Severe and Refractory Glaucoma: 6-Month Outcomes. J Glaucoma 27:849–855. https://doi.org/10.1097/IJG.000000000001019

27. ElMallah MK, Berdahl JP, Williamson BK et al (2020) Twelve-month outcomes of stand-alone excisional goniotomy in mild to severe glaucoma. Clin Ophthalmol 14:1891–1897. https://doi.org/10.2147/OPTH.S256423

28. Toteberg-Harms M, Hanson JV, Funk J (2013) Cataract surgery combined with excimer laser trabeculotomy to lower intraocular pressure: effectiveness dependent on preoperative IOP. BMC Ophthalmol 13:24. https://doi.org/10.1186/1471-2415-13-24

29. Chen PP, Lin SC, Junk AK et al (2015) The Effect of Phacoemulsification on Intraocular Pressure in Glaucoma Patients: A Report by the American Academy of Ophthalmology. Ophthalmolog 122:1294–1307. https://doi.org/10.1016/j.ophtha.2015.03.021

30. Chang EK, Gupta S, Chachanidze M et al (2016) Clinical results with the Trabectome, a novel surgical device for treatment of open-angle glaucoma. Sci Rep 11:8910. https://doi.org/10.1038/s41598-021-88358-6

31. Tanito M, Matsuo M (2019) Ab-interno trabeculotomy-related glaucoma surgeries. Taiwan J Ophthalmol 9:67–71. https://doi.org/10.4103/j.to.jto_38_19

32. Minckler D, Baerveldt G, Ramirez MA et al (2006) Clinical results with the Trabectome, a novel surgical device for treatment of primary open-angle glaucoma. Trans Am Ophthalmol Soc 104:40–50

33. Tanito M (2018) Microhook ab interno trabeculotomy, a novel minimally invasive glaucoma surgery. Clin Ophthalmol 12:43–48. https://doi.org/10.2147/OPHTH.S152406

34. Chin S, Nitta T, Shinmei Y et al (2012) Reduction of intraocular pressure using a modified 360-degree suture trabeculotomy technique in primary and secondary open-angle glaucoma: a pilot study. J Glaucoma 21:401–407. https://doi.org/10.1097/IJG.0b013e318218240c

35. Gordon MO, Beiser JA, Brandt JD et al (2002) The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 120:714–720. https://doi.org/10.1001/archoph.120.6.714

36. Minckler D, Mosaed S, Dustin L et al (2008) Trabectome (trabeculectomy-internal approach): additional experience and extended follow-up. Trans Am Ophthalmol Soc 106:149–159

37. Jordan JF, Wecker T, van Oterendorp C et al (2013) Trabectome surgery for primary and secondary open angle glaucomas. Graefes Arch Clin Exp Ophthalmol 251:2753–2760. https://doi.org/10.1007/s00417-013-2500-7

38. Grover DS, Godfrey DG, Smith O et al (2014) Gonioscopy-assisted transluminal trabeculotomy, ab interno trabeculotomy: technique report and preliminary results. Ophthalmology 121:855–861. https://doi.org/10.1016/j.ophtha.2013.11.001

39. Bao W, Kawase K, Huang H et al (2019) The long-term outcome of trabeculectomy: comparison with filtering surgery in Japan. BMC Ophthalmol 19:99. https://doi.org/10.1186/s12886-019-1107-0

40. Nichamin LD (2009) Glaukos iStent Trabecular Micro-Bypass. Middle East Afr J Ophthalmol 16:138–140. https://doi.org/10.4103/0974-9233.56227

41. Samuelson TW, Katz LJ, Wells JM et al (2011) Randomized evaluation of the trabecular micro-bypass stent with phacoemulsification in patients with glaucoma and cataract. Ophthalmology 118:459–467. https://doi.org/10.1016/j.jfo.2010.07.007

42. Spiegel D, Wetzel W, Neumann T et al (2009) Coexistent primary open-angle glaucoma and cataract: interim analysis of a trabecular micro-bypass stent and concurrent cataract surgery. Eur J Ophthalmol 19:393–399. https://doi.org/10.1177/11206721090190311

43. Craven ER, Katz LJ, Wells JM et al (2012) Cataract surgery with trabecular micro-bypass stent implantation in patients with mild-to-moderate open-angle glaucoma and cataract: two-year follow-up. J Cataract Refract Surg 38:1339–1345. https://doi.org/10.1016/j.jcrs.2012.03.025

44. Katz LJ, Erb C, Carceller GA et al (2015) Prospective, randomized study of one, two, or three trabecular bypass stents in open-angle glaucoma subjects on topical hypotensive medication. Clin Ophthalmol 9:2313–2320. https://doi.org/10.2147/OPTH.S96695

45. Khan M, Saheb H, Neelakantan A et al (2015) Efficacy and safety of combined cataract surgery with 2 trabecular microbypass stents versus ab interno trabeculotomy. J Cataract Refract Surg 41:1716–1724. https://doi.org/10.1016/j.jcrs.2014.12.061

46. Wang Q, Harasymowycz P (2015) Short-term intraocular pressure elevations after combined phacoemulsification and implantation of two trabecular micro-bypass stents: prednisolone versus Loteprednol. J Ophthalmol 2015:341450. https://doi.org/10.1155/2015/341450

47. Popovic M, Campos-Moller X, Saheb H et al (2018) Efficacy and adverse event profile of the iStent and iStent Inject Trabecular Micro-bypass for open-angle glaucoma: a meta-analysis. J Curr Glaucoma Pract 12:67–84. https://doi.org/10.5005/jp-journals-10008-1248

48. Gimbel HV, Meyer D, DeBroff BM et al (1995) Intraocular pressure response to combined phacoemulsification and trabeculotomy ab externo versus phacoemulsification alone in primary open-angle glaucoma. J Cataract RefractSur
56. Suzuki R, Kuroki S, Fujiwara N (1997) Ten-year follow-up of intraocular pressure after phacoemulsification and aspiration with intraocular lens implantation performed by the same surgeon. Ophthalmologica 211:79–83. https://doi.org/10.1159/000310763

57. Tong JT, Miller KM (1998) Intraocular pressure change after sutureless phacoemulsification and foldable posterior chamber lens implantation. J Cataract Refract Surg 24:256–262. https://doi.org/10.1016/s0886-3350(98)80208-3

58. Bhallil S, Andalloussi IB, Chraibi F et al (2009) Changes in intraocular pressure after clear corneal phacoemulsification in normal patients. Oman J Ophthalmol 2:111–113. https://doi.org/10.4103/0974-620X.57309

59. Kim DD, Doyle JW, Smith MF (1999) Intraocular pressure reduction following phacoemulsification cataract extraction with posterior chamber lens implantation in glaucoma patients. Ophthalmic Surg Lasers 30:37–40

60. Goldmann H (1951) Out-flow pressure, minute volume and resistance of the anterior chamber flow in man. Doc Ophthalmol 5–6:278–356. https://doi.org/10.1007/BF0043664

61. Brubaker RF (2004) Goldmann’s equation and clinical measures of aqueous dynamics. Exp Eye Res 78:633–637. https://doi.org/10.1016/j.exer.2003.07.002

62. Neuhann R, Neuhann T (2020) Second-generation trabecular micro-bypass stent implantation: Retrospective analysis after 12- and 24-month follow-up. Eye Vis (Lond) 7:1. https://doi.org/10.1186/s40662-019-0169-7

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.